Single-Dose Pharmacokinetics of Amprenavir, a Human Immunodeficiency Virus Type 1 Protease Inhibitor, in Subjects With Normal or Impaired Hepatic Function

Antimicrobial Agents and Chemotherapy - United States
doi 10.1128/aac.44.4.821-826.2000
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Microbiology

Related search

Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, Following Oral Administration of Single Doses to HIV-Infected Adults

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1999English

Pharmacokinetics and Safety of a Single Oral Dose of Peficitinib (ASP015K) in Japanese Subjects With Normal and Impaired Hepatic Function

Clinical Pharmacology in Drug Development
PharmacologyPharmaceutical Science
2019English

Synaptic Dysfunction in Human Immunodeficiency Virus Type-1-Positive Subjects: Inflammation or Impaired Neuronal Plasticity?

Journal of Internal Medicine
Internal Medicine
2013English

Evaluation of the Pharmacokinetics and Safety of a Single Oral Dose of Fasiglifam in Subjects With Normal or Varying Degrees of Impaired Renal Function

Drugs in R and D
Pharmacology
2014English

Human Immunodeficiency Virus Type 1 Protease-Correlated Cleavage Site Mutations Enhance Inhibitor Resistance

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
2009English

Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease Following Different Protease Inhibitor Treatments

Journal of Virology
Insect ScienceImmunologyMicrobiologyVirology
2003English

In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2000English

Single-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in Patients With Human Immunodeficiency Virus Infection.

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1997English

Crystal Structure of Human Immunodeficiency Virus (HIV) Type 2 Protease in Complex With a Reduced Amide Inhibitor and Comparison With HIV-1 Protease Structures.

Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
1993English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy